9774 -- To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes. | Poliscope

To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.

9774

119th Congress

Health

In Committee

Legislative Progress

✓

Introduced

Committee

Floor Vote

Other Chamber

Enacted

Introduced

July 20, 2026

Latest Action

July 20, 2026

Primary Sponsor

Robert E. LattaRepublican(OH)

Momentum (last 30 days)

score

0 actions · 0 new cosponsors · 0 votes

Speed vs cohort

0pct

0d open

vs 10,940 other HR bills in the 119th — cohort avg 30d

Summary

No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.

Lobbying filings that explicitly cite this bill (2)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Filing registrants (2)

CENTER FOR AMERICAN PROGRESS ACTION FUND (1)CHATTEM, INC D/B/A OPELLA (1)

CHATTEM, INC D/B/A OPELLAclient→CHATTEM, INC D/B/A OPELLA

2026 · third_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Nonprescription Drug Innovation Act (H.R.9774); dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE); HR.10336-Dietary Supplement Innovation Act; issues related to Rx to OTC Switch/PDUFA reauthorization.

Client expense: $180,000 · Firm income: Not reported

H.R.9774